HUTCHMED (China) (HCM) H1 2025 earnings summary

Executive summary

• Net income reached $455 million in H1 2025, primarily from a $609 million gain on the partial divestment of SHPL, with cash and short-term investments rising to $1.36 billion.

• FRUZAQLAⓇ/Zecla achieved 25% global sales growth, expanding into over 30 countries, while ELUNATEⓇ, SULANDAⓇ, and ORPATHYSⓇ saw declines in China due to competition and regulatory headwinds.

• Multiple late-stage pipeline advancements, including approvals and filings for Savolitinib, Fruquintinib, and Tazemetostat in new indications.

• ATTC (Antibody Targeted Therapy Conjugate) platform progressing, with first clinical trial initiation planned for late 2025.

• Oncology revenue guidance for 2025 revised to $270–$350 million due to milestone income delays and regulatory review timing.

Financial highlights

• H1 2025 total revenue was $277.7 million, down 9–10% year-over-year, with Oncology/Immunology revenue at $143.5 million, down 15%.

• Net income attributable to shareholders was $455 million, up from $25.8 million in H1 2024, driven by the SHPL divestment gain.

• R&D investment reached $72 million, reflecting multiple NDA submissions and cost reductions.

• Cash and short-term investments increased to $1.36 billion, supporting global development and acquisitions.

• Operating expenses decreased to $281.2 million, reflecting R&D and selling/admin cost reductions.

Outlook and guidance

• Oncology revenue guidance for 2025 revised to $270–$350 million, reflecting milestone income phasing and regulatory review delays.

• Anticipate improved sales growth in H2 2025, driven by new approvals, expanded reimbursement, and international launches.

• Multiple pivotal trial readouts (SAFFRON, SANOVO, SAMETA) expected in late 2025 and early 2026.

• ATTC platform to enter clinical trials, with potential for rapid proof-of-concept and future product pipeline expansion.

• Medium-term strategy focuses on leveraging strong cash for product acquisitions and global ATTC development.